Chronic Fatigue Not Uncommon Among Childhood Blood Cancer Survivors

Adult survivors of some childhood blood cancers face an increased risk of suffering from chronic fatigue, according to a new study.

A constant lack of energy that doesn't get better over time and doesn't improve with additional rest are hallmarks of chronic fatigue syndrome. It can be a very disruptive problem, leading to a diminished quality-of-life, an inability to maintain employment in some and even an inability to do simple daily activities.

The study pinpointed both acute lymphoblastic leukemia (ALL) as well as lymphoma experienced by adults during childhood and determined that when compared to the general population, chronic fatigue was three times more likely in these cancer survivors. They found that the prevalence of the problem was 27 percent among the cancer survivors compared to 8 percent among controls.

The findings, by Hanne Hamre, MD and colleagues Oslo University Hospital and University of Oslo Norway, were published in the Journal of Adolescent and Young Adult Oncology.

According journal Editor-in-Chief Leonard S. Sender, MD, of the University of California, Irvine and CHOC Children's Hospital:

Chronic fatigue in cancer survivors is often an under-appreciated complication of treatment. There is a general belief that after successful treatment a survivor should be able to bounce back without lasting effects. Hamre and colleagues demonstrate that fatigue is a larger problem than generally appreciated. Their findings put a spotlight on this key aspect of cancer survivorship and serve to encourage the medical community to communicate with cancer survivor patients about possible chronic fatigue.

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap